The CVUE ADVANCED (hioxifilcon D) Single Vision Contact Lenses are indicated for daily wear for the correction of refractive ametropia (myopia, hyperopia and astigmatism) and presbyopia in aphakic and/or not-aphakic persons with nondiseased eyes. The lens may be worn by persons who require up to 3.00 Diopters of add and who exhibit astigmatism of up to 0.75 Diopters that does not interfere with visual acuity.

The CVUE ADVANCED (hioxifilcon D) Toric and Multifocal Toric Contact Lenses are indicated for daily wear for the correction of refractive ametropia (myopia and hyperopia), presbyopia and astigmatism up to 4.00 diopters in aphakic and/or notaphakic persons with non-diseased eyes.

Eye care practitioners may prescribe the lens for frequent/planned replacement wear, with cleaning, disinfection and scheduled replacement. When prescribed for frequent/planned replacement wear, the lens may be disinfected using a chemical disinfection system.

Device Description

CVUE ADVANCED (hioxifilcon D) soft contact lenses are semi-scleral flexible shells which cover the cornea and may cover a portion of the adjacent sclera and are available as aspheric single vision, multifocal, toric multifocal designs. Torics have a toroidal posterior optic zone, and multifocals have the most plus power is in the center of the lens, with the power progressively becoming more minus towards the periphery. Torics have the option of dynamic axis stabilization (double slab off) or prism ballast stabilization. All lenses share a base curve with a flattened peripheral curve which approximates the curvature of the sclera. The lens material, (hioxifilcon D), is a non-ionic copolymer of 2-hydroxyethyl methacrylate (2-HEMA) and 2, 3-dihydroxypropyl methacrylate (Glycerol Methacrylate, GMA) and crosslinked with ethylene glycol dimethacrylate (EGDMA). It consists of 46% hioxifilicon D and 54% water by weight when immersed in normal buffered saline solution. The lens is available with or without a blue visibility handling tint, phthalocyanato (2) -(copper).

The CVUE ADVANCED (hioxifilcon D) soft contact lens is a hemispherical shell of the following dimensions:

Chord diameter: 12.5 to 17.0mm
Center thickness: 0.13 to 0.73; varies with power
Base curve: 7.0 to 10.5mm
Powers: -20.00 to +20.00 diopters
ADD powers (multifocal): Up to +3.00 diopters
Cylinder (toric): Up to 4.00 diopters
Axis (toric): 0° to 180° in 1° steps
Axis stabilization (toric): prism ballast; or dynamic (double slab off)
Optical zone diameters: 5.0 to 10.0mm

The physical/optical properties of the lens are:
Refractive Index 1.408 (hydrated)
Light Transmission – tinted greater than 90%
Water Content 54%
Specific Gravity 1.299 (dry)
Oxygen Permeability (Dk Value) 23 x 10-11 Fatt Units (cm2/sec) (ml O2/ml x mm Hg @ 35°C), ANSI Z80.20:2004 upgraded polarographic method corrected for boundary-layer and edge effects

AI/ML Overview

This document is a 510(k) Premarket Notification for a contact lens device, not an AI/ML medical device. Therefore, the information typically requested regarding acceptance criteria, study design, and performance metrics for AI/ML models (e.g., sample sizes for training/test sets, ground truth establishment, expert qualifications, MRMC studies, standalone performance) is not applicable or present in this submission.

The document discusses the substantial equivalence of the C-VUE® Advanced™ (hioxifilcon D) Soft (hydrophilic) Contact Lens for Daily Wear to predicate devices based on intended use, manufacturing, safety profile, physical construction, and indications for use. It asserts that the device does not raise any new or different questions of safety and effectiveness.

However, to respond to the prompt's structure where possible, I will extract relevant compliance information assuming a direct mapping, even if the context is different.

Acceptance Criteria and Study for C-VUE® Advanced™ (hioxifilcon D) Soft (hydrophilic) Contact Lens

This document describes the regulatory submission for a contact lens, not an AI/ML medical device. Therefore, the acceptance criteria and study details are related to demonstrating substantial equivalence for a physical medical device. The information provided does not align with the typical data requested for AI/ML device performance.

Here's an attempt to answer the prompt's questions based on the provided text, noting where the information is not applicable:

1. A table of acceptance criteria and the reported device performance

The document does not explicitly state "acceptance criteria" in the context of quantifiable performance metrics for a study or "reported device performance" in a numerical sense as would be found for an algorithm. Instead, it refers to demonstrating "substantial equivalence" to predicate devices. The "performance" discussed relates to the physical and optical properties of the lens and its "safety and effectiveness" being equivalent to existing devices.

Acceptance Criterion (Implicit)	Reported Device Performance (Implicit)
Intended Use: Device's intended use matches predicate.	"The C-VUE® Advanced™ (hioxifilcon D) Soft (hydrophilic) Contact Lens for Daily Wear is substantially equivalent to the predicate device identified below in terms of intended use."
Safety Profile: Established safety (pre-clinical toxicology, manufacturing/chemistry data) is equivalent to predicate.	"The established safety profile (pre-clinical toxicology and manufacturing/chemistry data) of the device the same to the CVUE ADVANCED (hioxifilcon D), 510(k) K082853."
Physical Construction: Physical construction is equivalent to predicate.	"Physical construction and safety and effectiveness do not change from the predicate devices."
Indications for Use: Indications for use are equivalent to predicate.	"The CVUE ADVANCED (hioxifilcon D) Single Vision Contact Lenses indications for use do not change."
Manufacturing/Packaging/Sterilization: Procedures are the same as currently marketed devices.	"The device will undergo manufacturing, packaging and sterilization procedures that are the same as devices currently manufactured, marketed and distributed by Unilens Corp., USA."
No New Questions of Safety/Effectiveness: Device does not raise new questions.	"This meets the requirements per section 510(k) of the act regarding substantial equivalence and does not raise any new or different questions of safety and effectiveness than the predicate devices identified above."
Physical/Optical Properties: Meet specified ranges/values.	Refractive Index: 1.408 (hydrated)Light Transmission – tinted: greater than 90%Water Content: 54%Specific Gravity: 1.299 (dry)Oxygen Permeability (Dk Value): 23 x 10^-11 Fatt Units (cm²/sec) (ml O2/ml x mm Hg @ 35°C), ANSI Z80.20:2004 upgraded polarographic method corrected for boundary-layer and edge effects

2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)

Sample Size: Not applicable. This is a 510(k) submission for a physical medical device demonstrating substantial equivalence, not an AI/ML device with a test set of data. The "study" here is a comparison to predicate devices, not clinical trial data with specific patient sample sizes for performance evaluation in the typical sense.
Data Provenance: Not applicable in the context of an AI/ML test set. The submission refers to a previous 510(k) for the safety profile (K082853), implying existing data from that submission.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

Not applicable. There is no "test set" of data or "ground truth" (as in expert-labeled data for an algorithm) established by experts in this type of submission. The evaluation is based on established regulatory standards and comparison to predicate devices.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set

Not applicable. No test set or expert adjudication related to algorithm performance is present.

5. If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

Not applicable. This relates to an AI/ML device, which this contact lens is not.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

Not applicable. This relates to an AI/ML device, which this contact lens is not.

7. The type of ground truth used (expert concensus, pathology, outcomes data, etc)

Not applicable. The concept of "ground truth" as it applies to AI/ML model training and validation is not relevant here. The "truth" for this submission is regulatory compliance and demonstrating equivalence to legally marketed predicate devices, supported by manufacturing data, physical properties, and a previously established safety profile.

8. The sample size for the training set

Not applicable. There is no "training set" as this is not an AI/ML device.

9. How the ground truth for the training set was established

Not applicable. There is no "training set" or "ground truth" for it, as this is not an AI/ML device.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo features a stylized design of three human profiles facing to the right, with flowing lines suggesting movement or connection. The profiles are arranged in a way that they appear to be overlapping. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the design.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

October 30, 2014

Unilens Corp., USA Mr. Alan J. Frazer Director of Quality Assurance 10431 72nd Street, North Largo, FL 33777

Re: K142851

Trade/Device Name: C-VUE® Advanced™ (hioxifilcon D) Soft (hydrophilic) Regulation Number: 21 CFR 886.5925 Regulation Name: Lenses, soft contact, daily wear Regulatory Class: Class II Product Code: LPL Dated: September 29, 2014 Received: September 30, 2014

Dear Mr. Frazer:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing

{1}------------------------------------------------

(21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Kesia Y. Alexander -S

for Malvina B. Eydelman, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K142851

Device Name

CVUE® Advanced™ (hioxifilcon D) Soft (hydrophilic) Contact Lens for Daily Wear

Indications for Use (Describe)

Type of Use (Select one or both, as applicable)
☑ Prescription Use (Part 21 CFR 801 Subpart D)	☐ Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(k) Summary

Applicant Information

Date prepared:	17 Sep 2014
Name:Address:	Unilens Corp., USA10431 72nd Street, NorthLargo, FL 33777
Contact person:	Alan J. FrazerDirector of Quality Assurance
Phone number:	(727) 544-2531
Fax number:	(727) 545-1883

Device Information

Device classification:	Class II
Classification number:	LPL
Classification name:	Lenses, Soft Contact, Daily Wear
Trade name:	C-VUE® Advanced™ (hioxifilcon D) Soft (hydrophilic) Contact Lens

Equivalent device

The C-VUE® Advanced™ (hioxifilcon D) Soft (hydrophilic) Contact Lens for Daily Wear is substantially equivalent to the predicate device identified below in terms of intended use.

Predicate devices:

LifeStyle MV2 Toric (polymacon) Soft (Hydrophilic) Multifocal Contact Lens for Daily Wear

C-VUE® Advanced™ (hioxifilcon D) Soft (hydrophilic) Contact Lens for Daily Wear

Device description

{4}------------------------------------------------

and 54% water by weight when immersed in normal buffered saline solution. The lens is available with or without a blue visibility handling tint, phthalocyanato (2) -(copper).

The CVUE ADVANCED (hioxifilcon D) soft contact lens is a hemispherical shell of the following dimensions:

Chord diameter:	12.5 to 17.0mm
Center thickness:	0.13 to 0.73; varies with power
Base curve:	7.0 to 10.5mm
Powers:	-20.00 to +20.00 diopters
ADD powers (multifocal):	Up to +3.00 diopters
Cylinder (toric):	Up to 4.00 diopters
Axis (toric):	0° to 180° in 1° steps
Axis stabilization (toric):	prism ballast; ordynamic (double slab off)
Optical zone diameters:	5.0 to 10.0mm

The physical/optical properties of the lens are:
Refractive Index	1.408 (hydrated)
Light Transmission – tinted	greater than 90%
Water Content	54%
Specific Gravity	1.299 (dry)
Oxygen Permeability (Dk Value)	23 x 10-11 Fatt Units (cm2/sec) (ml O2/ml x mm
	Hg @ 35°C), ANSI Z80.20:2004 upgraded polarographic methodcorrected for boundary-layer and edge effects

Intended Use (Indications)

{5}------------------------------------------------

Substantial equivalence

The CVUE ADVANCED (hioxifilcon D) Single Vision Contact Lenses will be manufactured according using the specified process controls and the quality management system currently in place. The device will underqo manufacturing, packaging and sterilization procedures that are the same as devices currently manufactured, marketed and distributed by Unilens Corp., USA.

The established safety profile (pre-clinical toxicology and manufacturing/chemistry data) of the device the same to the CVUE ADVANCED (hioxifilcon D), 510(k) K082853.

The CVUE ADVANCED (hioxifilcon D) Single Vision Contact Lenses indications for use do not change

Physical construction and safety and effectiveness do not change from the predicate devices.

This meets the requirements per section 510(k) of the act regarding substantial equivalence and does not raise any new or different questions of safety and effectiveness than the predicate devices identified above.

Regulation Number and Section

§ 886.5925 Soft (hydrophilic) contact lens.

(a)
Identification. A soft (hydrophilic) contact lens is a device intended to be worn directly against the cornea and adjacent limbal and scleral areas of the eye to correct vision conditions or act as a therapeutic bandage. The device is made of various polymer materials the main polymer molecules of which absorb or attract a certain volume (percentage) of water.(b)
Classification. (1) Class II if the device is intended for daily wear only.(2) Class III if the device is intended for extended wear.
(c)
Date PMA or notice of completion of a PDP is required. As of May 28, 1976, an approval under section 515 of the act is required before a device described in paragraph (b)(2) of this section may be commercially distributed. See § 886.3.